IMS P&MA can help boost revenues by providing and supplementing strategies aimed to get products to the market faster. IMS P&MA consultants create strong cases for reimbursement by identifying, researching and analysing products’ benefits over market comparators, for fast market entry that creates revenue streams sooner.
We provide a range of product assessment services, including determination of optimum product pricing, through to preparing product value and access (PVA) kits. IMS consultants undertake market research with physicians and patients to evaluate the acceptance and feasibility for new product launches – information that is crucial for key stakeholders.
We offer market forecasts to show the potential uptake of drugs in new and existing therapeutic areas, and other health care services, expressed in terms of number of patients, packs sold or revenue over time. IMS applies leading edge economic evaluation and current modelling software to create evidence-based evaluations.
We work with our clients to establish clear understanding of the impact of generics entering the market and develop outcomes that qualify impact in real dollar terms. The consultancy team can evaluate the cost of recent and historic government policy changes and indicate affects and impacts on listed products.
These insights help clients to fine tune pricing strategies and tactics to achieve maximum market share.